ICB therapies in hematological malignancies have primarily started with anti-CTLA-4 (Ipilimumab) and anti PD-1/PD-L1 antibodies (Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, and Durvalumab) and there are numerous clinical trials evaluating their therapeutic benefits alone or in combination with other treatments (Table S1); however, they have shown clinical benefits mostly in certain types of hematological malignancies. Here, CTLA4 is linked to hematologic disorder.